Lifecore Biomedical (NASDAQ:LFCR - Get Free Report) posted its quarterly earnings data on Thursday. The company reported ($0.19) earnings per share for the quarter, missing the consensus estimate of ($0.14) by ($0.05), Zacks reports. Lifecore Biomedical had a negative net margin of 12.52% and a negative return on equity of 315.23%. The company had revenue of $35.15 million during the quarter, compared to analyst estimates of $33.23 million. Lifecore Biomedical updated its FY 2025 guidance to EPS.
Lifecore Biomedical Trading Up 2.2 %
NASDAQ:LFCR traded up $0.11 during trading hours on Tuesday, hitting $5.21. The stock had a trading volume of 417,816 shares, compared to its average volume of 222,834. The business's 50 day moving average is $6.12 and its 200-day moving average is $6.25. The company has a market cap of $192.90 million, a price-to-earnings ratio of -9.30 and a beta of 0.80. Lifecore Biomedical has a one year low of $3.68 and a one year high of $7.99. The company has a debt-to-equity ratio of 9.21, a quick ratio of 1.21 and a current ratio of 2.32.
Analyst Ratings Changes
Separately, Stephens reissued an "equal weight" rating and issued a $6.00 price target on shares of Lifecore Biomedical in a research note on Friday, January 3rd.
Get Our Latest Stock Report on Lifecore Biomedical
Insider Activity
In other Lifecore Biomedical news, CEO Paul Josephs purchased 17,000 shares of the stock in a transaction on Wednesday, January 8th. The stock was bought at an average cost of $5.74 per share, for a total transaction of $97,580.00. Following the completion of the acquisition, the chief executive officer now directly owns 559,717 shares of the company's stock, valued at $3,212,775.58. The trade was a 3.13 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 32.20% of the stock is owned by company insiders.
About Lifecore Biomedical
(
Get Free Report)
Lifecore Biomedical, Inc, together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States and internationally. The company engages in the manufacturing of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures.
See Also
Before you consider Lifecore Biomedical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Lifecore Biomedical wasn't on the list.
While Lifecore Biomedical currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
